Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Common Equity (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Common Equity for 17 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • Quarterly Common Equity fell 32.47% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, down 32.47% year-over-year, with the annual reading at $1.0 billion for FY2025, 32.47% down from the prior year.
  • Common Equity hit $1.0 billion in Q4 2025 for Integra Lifesciences Holdings, up from $1.0 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.8 billion in Q4 2022 to a low of $1.0 billion in Q3 2025.
  • Historically, Common Equity has averaged $1.5 billion across 5 years, with a median of $1.6 billion in 2023.
  • Biggest five-year swings in Common Equity: rose 16.74% in 2021 and later tumbled 32.47% in 2025.
  • Year by year, Common Equity stood at $1.7 billion in 2021, then rose by 7.1% to $1.8 billion in 2022, then dropped by 12.0% to $1.6 billion in 2023, then decreased by 2.68% to $1.5 billion in 2024, then crashed by 32.47% to $1.0 billion in 2025.
  • Business Quant data shows Common Equity for IART at $1.0 billion in Q4 2025, $1.0 billion in Q3 2025, and $1.0 billion in Q2 2025.